3 Branded Generics Marketer, Cardiac and Gastro Brands Company and Over-the-Counter Formulations Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma
- October 27, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma: ROE of 13.8% to 18.7% and FY22 to FY26 revenue CAGR of 12.1% to 18.6%. Prices as of 26 Oct 2026.
Quick Answer
The three branded generics, cardiac and OTC pharma stocks to watch are Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma. Their return on equity ranges from 13.8% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 18.6%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.
Branded generics, cardiac and OTC pharma stocks offer a focused view of a sector where demand keeps widening. Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma cover a branded generics marketer, a cardiac and gastro brands company and an over-the-counter formulations maker.
This list covers three branded generics, cardiac and OTC pharma stocks with complete current figures: Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generics, Cardiac and OTC Pharma Stocks?
Branded generics, cardiac and OTC pharma stocks are listed drug makers that market branded generics in India, lead in heart and stomach care and export self-care products to developed markets. Their earnings depend on prescriptions, brand strength, launches and plant quality.
Branded Generics, Cardiac and OTC Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 1,780.2 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| JB Chemicals and Pharmaceuticals | 2,408.9 | 38,731 | 54.6 | 35.8 | 17.1 | 0.00 |
| Marksans Pharma | 296.65 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Emcure Pharmaceuticals and Marksans Pharma trade at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing branded generics, cardiac and OTC pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Branded Generics, Cardiac and OTC Pharma Stocks Have a Strong Roadmap in India?
Branded generics, cardiac and OTC pharma stocks have a strong roadmap in India because wider healthcare access, trusted brands and demand for self-care products abroad keep widening the revenue base.
- Brand marketing. Strong doctor networks help brands scale.
- Chronic care. Cardiac and gastro brands retain prescribers.
- Self-care exports. Over-the-counter products sell across developed markets.
Why Emcure Pharmaceuticals Features Among These Branded Generics, Cardiac and OTC Pharma Stocks
Among the branded generics, cardiac and OTC pharma stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why JB Chemicals and Pharmaceuticals Features Among These Branded Generics, Cardiac and OTC Pharma Stocks
Among the Pune branded generics company shares on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.
Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.
The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.
Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.
Why Marksans Pharma Features Among These Branded Generics, Cardiac and OTC Pharma Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Emcure Pharmaceuticals vs JB Chemicals and Pharmaceuticals vs Marksans Pharma on Key Financials
The table below sets the three branded generics, cardiac and OTC pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| JB Chemicals and Pharmaceuticals | 2,463 | 4,208 | 14.3% | 709 | 16.9% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Emcure Pharmaceuticals has the largest FY26 revenue at Rs 9,335 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with branded generics, cardiac and OTC pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Branded Generics, Cardiac and OTC Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these branded generics, cardiac and OTC pharma stocks, the main points are: Long-term Pune branded generics company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generics, cardiac and OTC pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generics, Cardiac and OTC Pharma Stocks
Branded generics, cardiac and OTC pharma stocks reward patient research into demand, execution and financial strength. Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma each have a clear plan to grow. Based on the 26 October 2026 close, Emcure Pharmaceuticals trades at Rs 1,780.2, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Marksans Pharma at Rs 296.65. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generics, cardiac and OTC pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generics, cardiac and OTC pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generics, cardiac and OTC pharma stocks?
Ans. Branded generics, cardiac and OTC pharma stocks are listed drug makers that market branded generics in India, lead in heart and stomach care and export self-care products to developed markets. Their earnings depend on prescriptions, brand strength, launches and plant quality. This list looks at three of them, Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.
Which branded generics, cardiac and OTC pharma stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, JB Chemicals and Pharmaceuticals and Marksans Pharma. Based on the 26 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,780.2, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Marksans Pharma at Rs 296.65. Their return on equity ranges from 13.8% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 18.6%.
Why do branded generics, cardiac and OTC pharma stocks have a strong future roadmap in India?
Ans. Branded generics, cardiac and OTC pharma stocks have a strong roadmap in India because wider healthcare access, trusted brands and demand for self-care products abroad keep widening the revenue base. The main drivers are as follows. Brand marketing. Strong doctor networks help brands scale. Chronic care. Cardiac and gastro brands retain prescribers. Self-care exports. Over-the-counter products sell across developed markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has JB Chemicals and Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying branded generics, cardiac and OTC pharma stocks?
Ans. Investors should check a few risks before buying branded generics, cardiac and OTC pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generics, cardiac and OTC pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
